JP2006528627A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528627A5
JP2006528627A5 JP2006520939A JP2006520939A JP2006528627A5 JP 2006528627 A5 JP2006528627 A5 JP 2006528627A5 JP 2006520939 A JP2006520939 A JP 2006520939A JP 2006520939 A JP2006520939 A JP 2006520939A JP 2006528627 A5 JP2006528627 A5 JP 2006528627A5
Authority
JP
Japan
Prior art keywords
natural killer
killer cells
alloreactive
therapeutic antibody
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006520939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528627A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002637 external-priority patent/WO2005009466A1/en
Publication of JP2006528627A publication Critical patent/JP2006528627A/ja
Publication of JP2006528627A5 publication Critical patent/JP2006528627A5/ja
Pending legal-status Critical Current

Links

JP2006520939A 2003-07-24 2004-07-23 アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物 Pending JP2006528627A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48950903P 2003-07-24 2003-07-24
PCT/IB2004/002637 WO2005009466A1 (en) 2003-07-24 2004-07-23 Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells

Publications (2)

Publication Number Publication Date
JP2006528627A JP2006528627A (ja) 2006-12-21
JP2006528627A5 true JP2006528627A5 (enExample) 2007-07-26

Family

ID=34102891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006520939A Pending JP2006528627A (ja) 2003-07-24 2004-07-23 アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物

Country Status (4)

Country Link
US (1) US20060240005A1 (enExample)
EP (1) EP1648508A1 (enExample)
JP (1) JP2006528627A (enExample)
WO (1) WO2005009466A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019379A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP2493486A1 (en) * 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
AU2015300006B2 (en) 2014-08-07 2018-08-30 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
CA2998292A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
WO2018083080A2 (en) 2016-11-04 2018-05-11 Innate Pharma Nkp46 ligand
CA3128202A1 (en) * 2017-05-11 2018-11-15 Nantkwest, Inc. Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満 吉和 高活性nk細胞、およびその利用
WO2019154509A1 (en) 2018-02-09 2019-08-15 Pupil Labs Gmbh Devices, systems and methods for predicting gaze-related parameters
EP3750029A1 (en) 2018-02-09 2020-12-16 Pupil Labs GmbH Devices, systems and methods for predicting gaze-related parameters using a neural network
EP3749172B2 (en) 2018-02-09 2025-01-01 Pupil Labs GmbH Devices, systems and methods for predicting gaze-related parameters
US11537202B2 (en) 2019-01-16 2022-12-27 Pupil Labs Gmbh Methods for generating calibration data for head-wearable devices and eye tracking system
JP6697611B2 (ja) * 2019-05-20 2020-05-20 米満 吉和 高活性nk細胞、およびその利用
EP3979896B1 (en) 2019-06-05 2024-11-13 Pupil Labs GmbH Devices, systems and methods for predicting gaze-related parameters
WO2020253949A1 (en) 2019-06-18 2020-12-24 Pupil Labs Gmbh Systems and methods for determining one or more parameters of a user's eye
US12140771B2 (en) 2020-02-19 2024-11-12 Pupil Labs Gmbh Eye tracking module and head-wearable device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1041221A1 (zh) * 1998-08-11 2002-07-05 Idec药物公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
CA2532547C (en) * 2003-07-24 2020-02-25 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds

Similar Documents

Publication Publication Date Title
JP2006528627A5 (enExample)
TWI697334B (zh) 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
JP2009539841A5 (enExample)
CN109789196B (zh) 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
JP2009114201A5 (enExample)
CN113597328A (zh) 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
JP2012519712A5 (enExample)
JP2009518441A5 (enExample)
JP2019527678A5 (enExample)
JP2014533279A5 (enExample)
JP2016509582A5 (enExample)
JP2019502676A5 (enExample)
JP2009519257A5 (enExample)
RU2010112940A (ru) Комбинированная терапия антителами анти-cd20 типа i и типа ii
JP2006506333A5 (enExample)
JP2020510039A5 (enExample)
JP2009533367A5 (enExample)
JP2019518742A5 (enExample)
RU2011104955A (ru) Композиции антител
JP2006528626A5 (enExample)
US20150023972A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2015534579A5 (enExample)
JP2013518912A5 (enExample)
ES2860480T3 (es) Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
Frankel et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma